Leadership Lab: How To Spot When Employees Are About To Walk Away Employees rarely leave companies for one reason alone. In this column, Kaye/Bassman’s Michael Pietrack shares a framework that…
Recognition highlights WuXi Biologics’ commitment to delivering exceptional value and innovative solutions to its global clients. WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today…
New findings underscore Cefiderocol’s efficacy and reliability in managing complex, multidrug-resistant bacterial infections. Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) presents…
Replimune Soars Upon FDA Resubmission for Advanced Melanoma Drug Last month, investors’ hopes were dashed as Replimune suggested alignment had not yet been reached with the FDA on RP1’s future.…
The FDA approval marks Gazyva’s first non-oncology indication, expanding Roche’s presence into autoimmune disease treatment. The anti-CD20 antibody, developed by Roche’s Genentech along with Biogen and already approved for multiple…
Despite major therapeutic advances, patients with multiple myeloma continue to face relapse and resistance—demanding renewed focus and innovation. Recent headlines proclaim a ‘potential’ or ‘functional’ cure for multiple myeloma, but…
The investigational B7-H4–targeted antibody–drug conjugate HS-20089 demonstrates encouraging efficacy and manageable safety in patients with platinum-resistant ovarian cancer. Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK) today announced positive phase…
The World Health Organization confirms Fiji has eliminated trachoma as a public health problem, marking a major step toward global eye health goals. In a landmark public health achievement, Fiji…
Novartis Kisqali® Shows Sustained Five-Year Benefit in Broad Early Breast Cancer Population Novartis today released results from the five-year analysis of the pivotal Phase III NATALEE trial, confirming the long-term…
CHMP Recommends Scemblix for Newly Diagnosed CML in Europe, Offering Superior Efficacy and Tolerability Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European…
CHMP Recommends Saphnelo Subcutaneous Administration for SLE in the EU, Offering Convenient Self-Administration Option AstraZeneca has announced that its fully human monoclonal antibody Saphnelo (anifrolumab) has received a positive opinion…
CatalYm Unveils Promising Phase 2 GDFATHER-NEO Data: Visugromab Enhances Anti-Tumor Activity with PD-1 Inhibition in Neoadjuvant Muscle-Invasive Bladder Cancer CatalYm, a pioneering biotechnology company recognized globally for its focus on…
